South Africa Covid variant could be resistant to antibodies

 

Two major variants of the coronavirus have been detected in the recent past. They are the U.K. strain and the South African strain. Both these mutations can increase the transmission rates of the infections although they have not increased the death rates.

There is some extra concern with reference to the strain from South Africa as it seems to be more resistant to monoclonal antibodies. These antibodies, when given at an early stage of the infection, seemed to have helped some people fight the coronavirus.

The strain, 501Y.V2, could be “more of a threat” as it could avoid some of the protection that would be provided by treating a person with antibodies, according to Dr. Fauci, an infectious diseases expert and director of the National Institute of Allergy and Infectious Diseases.

When asked if he was worried about the new strain, he said that although it was not the kind of things he worries about, it was the kind of thing that he took seriously.

Dave Ricks, Chairman and CEO of pharmaceutical company Eli Lilly, said that the South African variant is giving the company some concern as it has more dramatic mutations to that spike protein which is the target of their treatment. He also added that theoretically the variant could evade their medicine.

Eli Lilly and Regeneron had been given emergency authorization, in November, in the U.S. to use specific medicine to treat the coronavirus infection.

To date the CDC has found about 72 cases of the U.K. variant but none of the South African variant.


Follow us on Google news for more updates and News










PLEASE READ THE IMPORTANT DISCLOSURES BELOW.

This content is being provided to you for informational purposes only. The content has been prepared by third parties not affiliated with CWEB Inc, a business. This content and any information contained therein, does not constitute a recommendation by CWEB to buy, sell or hold any security, financial product or instrument referenced in the content. This information neither is, nor should be construed as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. CWEB Inc. does not offer or provide any opinion regarding the nature, potential, value, suitability or profitability of any particular investment or investment strategy, and you shall be fully responsible for any investment decisions you make, and such decisions will be based solely on your evaluation of your financial circumstances, investment objectives, risk tolerance, and liquidity needs.

Unless stated otherwise, the web content provided by the CWEB family of companies is for educational purposes only. The information and tools provided neither are, nor should be construed, as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. or its affiliates. Unless stated otherwise, no information presented constitutes a recommendation by CWEB Inc. or its affiliates to buy, sell or hold any security, financial product or instrument discussed therein or to engage in any specific investment strategy.

Full Disclaimer

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.